Skip to main content

Advertisement

SpringerLink
Log in

2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan

  • Special Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The Japanese Breast Cancer Society initiated the breast cancer registry in 1975, which transitioned to the National Clinical Database-Breast Cancer Registry in 2012. This annual report presents data from 2020 and analyzes the ten-year mortality rates for those aged 65 and older. We analyzed data from 93,784 breast cancer (BC) cases registered in 2020 and assessed 10-year mortality rates for 36,279 elderly patients diagnosed between 2008 and 2012. In 2020, 99.4% of BC cases were females with a median age of 61. Most (65%) were diagnosed at early stages (Stage 0 or I). Breast-conserving surgery rates varied with stages: 58.5% at cStage I, 30.8% at cStage II, and 13.1% at cStage III. Sentinel lymph node biopsy was done in 73.6% of cases, followed by radiotherapy in 70% of those post-conserving surgery and chemotherapy in 21.1% post-surgery. Pathology showed that 63.4% had tumors under 2.0 cm, 11.7% had pTis tumors, and 77.3% had no axillary lymph node metastasis. ER positivity was seen in 75.1%, HER2 in 14.3%, and 30% had a Ki67 positivity rate above 30%. Across all stages and subtypes, there was a trend where the 10-year mortality rates increased for individuals older than 65 years. In Stage I, many deaths were not directly linked to BC and, for those with HER2-type and triple-negative BC, breast cancer-related deaths increased with age. Within Stage II, patients older than 70 years with luminal-type BC often experienced deaths not directly linked to BC, whereas patients below 80 years with HER2-type and triple-negative BC, likely had breast cancer-related deaths. In Stage III, breast cancer-related deaths were more common, particularly in HER2 and triple-negative BC. Our prognostic analysis underscores distinct mortality patterns by stage, subtype, and age in elderly BC patients. It highlights the importance of personalized treatment strategies, considering subtype-specific aggressiveness, age-related factors, and comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data that support the findings of this study are not openly available due to the nature of the clinical data used. The clinical data are derived from the registry, which is not an open database. The data were accessed by a designated statistician through an application process approved by academic societies. Therefore, we are unable to offer the original clinical data.

References

  1. Kubo M, et al. Annual report of the Japanese Breast Cancer Society Registry for 2016. Breast Cancer. 2020;27(4):511–8.

    Article  PubMed  Google Scholar 

  2. Hayashi N, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020;27(5):803–9.

    Article  PubMed  Google Scholar 

  3. Tada K, et al. Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30(2):157–66.

    Article  PubMed  Google Scholar 

  4. Iwamoto T, et al. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;156(3):485–94.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kataoka A, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160(1):163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kawai M, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med. 2016;5(6):1328–40.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Niikura N, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480–7.

    Article  CAS  PubMed  Google Scholar 

  8. Kubo M, et al. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat. 2019;178(3):647–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miyashita M, et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: a study from the Japanese Breast Cancer Registry. Ann Surg Oncol. 2019;26(8):2475–85.

    Article  PubMed  Google Scholar 

  10. Hojo T, et al. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. Breast Cancer. 2020;27(1):85–91.

    Article  MathSciNet  PubMed  Google Scholar 

  11. Ogiya R, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184(2):585–96.

    Article  PubMed  Google Scholar 

  12. Yamada A, et al. Systemic therapy and prognosis of older patients with Stage II/III breast cancer: a large-scale analysis of the Japanese Breast Cancer Registry. Eur J Cancer. 2021;154:157–66.

    Article  PubMed  Google Scholar 

  13. Aihara T, et al. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat. 2022;196(3):635–45.

    Article  CAS  PubMed  Google Scholar 

  14. Shimomura A, et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer. 2022;29(6):985–92.

    Article  PubMed  Google Scholar 

  15. Terada M, et al. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer. 2022;29(4):698–708.

    Article  PubMed  Google Scholar 

  16. Yotsumoto D, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer. 2022;29(1):1–8.

    Article  PubMed  Google Scholar 

  17. Adachi Y, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Res Treat. 2023;201(3):397–408.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the affiliated institutes participating in the Breast Cancer Registry of the JBCS for their efforts to register the patients’ data.

Funding

This work was funded by the Registration Committee of the Japanese Breast Cancer Society.

Author information

Authors and Affiliations

  1. Department of Breast and Thyroid Surgical Oncology, Hakuaikai Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0833, Japan

    Yasuaki Sagara

  2. Department of Healthcare Quality Assessment, University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑8655, Japan

    Hiraku Kumamaru & Naoko Kinukawa

  3. Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan

    Yasuaki Sagara & Naoki Niikura

  4. Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Seiryo‑Machi, Aoba‑Ku, Sendai, 980‑8574, Japan

    Minoru Miyashita

  5. Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Takaaki Konishi

  6. Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan

    Takayuki Iwamoto

  7. Radiation Therapy Department, Yokkaichi Municipal Hospital, Yokkaichi, Japan

    Naoko Sanuki

  8. Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, 1 Kanda‑Izumicho, Chiyoda‑Ku, Tokyo, 101‑8643, Japan

    Kenta Tanakura

  9. Division of Breast and Endocrine Surgery, Department of Surgery, School of Medicine, Hyogo Medical University, 1‑1 Mukogawa, Nishinomiya, Hyogo, Japan

    Masayuki Nagahashi

  10. Department of Breast Surgical Oncology, St. Luke’s International Hospital, 9‑1 Akashicho, Chuo‑Ku, Tokyo, 104‑8560, Japan

    Naoki Hayashi

  11. Department of Diagnostic Pathology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑Ku, Tokyo, 104‑0045, Japan

    Masayuki Yoshida

  12. School of Nursing and Rehabilitation Sciences, Showa University, Tokyo, Japan

    Chie Watanabe

  13. Tokyo Metropolitan Komagome Hospital, 3 Chome-18 Honkomagome, Bunkyo City, Tokyo, Japan

    Masakazu Toi

  14. Department of Medical Oncology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan

    Shigehira Saji

Authors
  1. Yasuaki Sagara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiraku Kumamaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Niikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minoru Miyashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takaaki Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takayuki Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Sanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenta Tanakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Nagahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masayuki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naoko Kinukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chie Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: YS, MM, NN, and TK. Assembly of data: HK and YS. Manuscript writing: YS. Critical revision of the manuscript for important intellectual content: The Registration Committee of the JBCS (NN, YS, TK, TI, NS, KT, MN, NH, MY, CW). Final approval of manuscript: All.

Corresponding author

Correspondence to Yasuaki Sagara.

Ethics declarations

Conflict of interest

YS have received honorariums from Pfizer, Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lily, Chugai Chugai Pharmaceutical Ltd, MSD, and Nihon Kayaku. HK have received honorariums from Chugai Pharmaceutical Ltd and consultation fee from EPS corporation. HK and NK are affiliated to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl. NN have received honorariums from Chugai, Eli Lilly, MSD, Daiichi Sankyo, AstraZeneca, and Pfizer. MM have received honorariums from Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Taiho, Daiichi Sankyo and Eisai. TK have received grants from Pfizer Co. Ltd, Kanzawa Medical Research Foundation and Japan Kampo Medicines Manufacturers Association. TI have received grants from Pfizer. MN have received honorariums from AstraZeneca, Eli Lilly, Pfizer, Novartis, Chugai, Taiho, Daiichi Sankyo, Eisai, Kyowa-Kirin, MSD, Myriad genetics, and Denka. NH have received grants from MSD, Chugai, and Konica Minolta Japan and honorariums from Eli Lilly, Astrazeneca, taiho, Eizai, ExactScience, Daiichi-Sankyo, Novartis, Pfizer, and Chugai. MY have received consulting fees from Eli Lilly and Chugai and honorariums from Agilent technologies, Chugai, Ono Yakuhin, MSD and Daiichi Sankyo. CW have received a honorarium from Chugai. MT have received research grants from Chugai, Takeda, Pfizer, Taiho, JBCRG assoc., KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, and Sanwa Shurui. MT have received honorariums from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, and Sysmex. SS have received grants from Taiho, Eisai, Chugai, Takeda, and Daiichi Sankyo and honorariums from Chugai/Roche Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo and MSD.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 44 KB)

Supplementary file2 (XLSX 20 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sagara, Y., Kumamaru, H., Niikura, N. et al. 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan. Breast Cancer 31, 179–184 (2024). https://doi.org/10.1007/s12282-023-01532-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-023-01532-8

Keywords

Search

Navigation